PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells

Backgroundc-Met is a tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF), and both c-Met and its ligand are expressed in a variety of tissues. C-Met/HGF/SF signaling is essential for normal embryogenesis, organogenesis, and tissue regeneration. Abnormal c-Met/HGF/SF signaling has been demonstrated in different tumors and linked to aggressive and metastatic tumor phenotypes. In vitro and in vivo studies have demonstrated inhibition of c-Met/HGF/SF signaling by the small-molecule inhibitor PHA665752. This study investigated c-Met and HGF expression in two neuroblastoma (NBL) cell lines and tumor tissue from patients with NBL, as well as the effects of PHA665752 on growth and motility of NBL cell lines. The effect of the tumor suppressor protein PTEN on migration and proliferation of tumor cells treated with PHA665752 was also evaluated.MethodsExpression of c-Met and HGF in NBL cell lines SH-EP and SH-SY5Y and primary tumor tissue was assessed by immunohistochemistry and quantitative RT-PCR. The effect of PHA665752 on c-Met/HGF signaling involved in NBL cell proliferation and migration was evaluated in c-Met-positive cells and c-Met-transfected cells. The transwell chemotaxis assay and the MTT assay were used to measure migration and proliferation/cell-survival of tumor cells, respectively. The PPAR-γ agonist rosiglitazone was used to assess the effect of PTEN on PHA665752-induced inhibition of NBL cell proliferation/cell-survival and migrationResultsHigh c-Met expression was detected in SH-EP cells and primary tumors from patients with advanced-stage disease. C-Met/HGF signaling induced both migration and proliferation of SH-EP cells. Migration and proliferation/cell-survival were inhibited by PHA665752 in a dose-dependent manner. We also found that induced overexpression of PTEN following treatment with rosiglitazone significantly enhanced the inhibitory effect of PHA665752 on NBL-cell migration and proliferation.Conclusionc-Met is highly expressed in most tumors from patients with advanced-stage, metastatic NBL. Furthermore, using the NBL cell line SH-EP as a model, PHA665752 was shown to inhibit cMet/HGF/SF signaling in vitro, suggesting c-Met inhibitors may have efficacy for blocking local progression and/or metastatic spread of c-Met-positive NBL in vivo. These are novel findings for this disease and suggest that further studies of agents targeting the c-Met/HGF axis in NBL are warranted

[1]  P. Lollini,et al.  The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. , 1995, Oncogene.

[2]  G. V. Vande Woude,et al.  Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. , 1996, Oncogene.

[3]  R. Sharp,et al.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Vuori,et al.  CAS/Crk Coupling Serves as a “Molecular Switch” for Induction of Cell Migration , 1998, The Journal of cell biology.

[5]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.

[6]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[7]  J. Laterra,et al.  Signaling pathways in the induction of c‐met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma , 2001, Journal of neurochemistry.

[8]  Michael P. Myers,et al.  PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  I. Pass,et al.  Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN , 2001, Current Biology.

[10]  E. Rosen,et al.  The Multisubstrate Adapter Gab1 Regulates Hepatocyte Growth Factor (Scatter Factor)–c-Met Signaling for Cell Survival and DNA Repair , 2001, Molecular and Cellular Biology.

[11]  H. Moritake,et al.  Analysis of PTEN/MMAC1 alteration in neuroblastoma. , 2001, Cancer genetics and cytogenetics.

[12]  B. Zbar,et al.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.

[13]  B. Teh,et al.  Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. , 2002, Cancer research.

[14]  R. Salgia,et al.  Activated c‐Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer , 2002, Journal of cellular and molecular medicine.

[15]  P. Houghton,et al.  Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. , 2003, Cancer research.

[16]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[17]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[18]  B. Evers,et al.  Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.

[19]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[20]  B. Evers,et al.  Activation of PPARγ increases PTEN expression in pancreatic cancer cells , 2003 .

[21]  R. Ross,et al.  A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. , 2003, Cancer letters.

[22]  J. Reis-Filho,et al.  Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas , 2003, Oncology.

[23]  D. Durden,et al.  Rac2 Specificity in Macrophage Integrin Signaling , 2003, Journal of Biological Chemistry.

[24]  J. Christensen,et al.  A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells , 2004, Clinical Cancer Research.

[25]  D. Hammond,et al.  Met receptor dynamics and signalling. , 2004, Current topics in microbiology and immunology.

[26]  Lothar Schweigerer,et al.  Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas , 2004, Cancer Research.

[27]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[28]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[29]  G. Woude,et al.  HGF/SF-Met signaling in tumor progression , 2005, Cell Research.

[30]  Charis Eng,et al.  Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. , 2005, Cancer research.

[31]  ChongfengGao.  HGF／SF-Met signaling in tumor progression , 2005 .

[32]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Christensen,et al.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. , 2005, Neoplasia.

[34]  Dmitri I Svergun,et al.  Structural basis of hepatocyte growth factor/scatter factor and MET signalling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Aburatani,et al.  A genomic analysis of adult T-cell leukemia , 2007, Oncogene.

[36]  Ravi Salgia,et al.  A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. , 2007, Cancer research.

[37]  Gary L Clayman,et al.  Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma , 2008, Head & neck.

[38]  J. Christensen,et al.  An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors , 2008, Clinical Cancer Research.